CGON (CG Oncology) Accumulated other comprehensive income (loss) : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. CG Oncology's Accumulated other comprehensive income (loss) for the quarter that ended in Mar. 2025 was $0.00 Mil.

CG Oncology Accumulated other comprehensive income (loss) Historical Data

The historical data trend for CG Oncology's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Accumulated other comprehensive income (loss) Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Accumulated other comprehensive income (loss)

CG Oncology Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial						-	-	-	-	-

CG Oncology Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

CG Oncology Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of CG Oncology's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.